Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec:600:110243.
doi: 10.1016/j.virol.2024.110243. Epub 2024 Sep 16.

Chimeric adenovirus-based herpes zoster vaccine with the tPA signal peptide elicits a robust T-cell immune response

Sun Ok Jang  1 , Jae Hyun Lee  1 , Yong-Ju Chung  1 , Hyun-Seok Oh  1 , Myeongcheol Shin  1 , Soo-Ok Kim  1 , Sun Pyo Hong  2
Affiliations

Chimeric adenovirus-based herpes zoster vaccine with the tPA signal peptide elicits a robust T-cell immune response

Sun Ok Jang et al. Virology. 2024 Dec.

Abstract

Herpes zoster (HZ), or shingles, is caused by reactivation of the varicella-zoster virus (VZV), which remains latent in the sensory ganglia until immunity wanes with age. The representative HZ vaccine, Shingrix is efficacious but causes side effects due to vaccine adjuvants. Therefore, the development of highly efficacious vaccines with minimal side effects is required. We developed chimeric adenovirus vector (ChimAd)-based HZ vaccine candidates encoding the VZV glycoprotein E (gE). These candidates include ChimAd-tPAgE, in which the signal peptide is replaced with tissue plasminogen activator (tPA), and ChimAd-WTgE, which retains the original signal peptide. C57BL/6 mice were immunized with VZV-vaccine candidates, and cellular and humoral immune responses were evaluated using interferon-γ ELISPOT and ELISA. The ChimAd-based HZ vaccines induced high levels of gE-specific antibodies and cell-mediated immunity. ChimAd-tPAgE (optimal dose: 1 × 107 IFU) elicited a more robust gE-specific T-cell response than Shingrix and Zostavax, showing potential as HZ prophylactic vaccines.

Keywords: Cell-mediated immunity; Chimeric adenovirus vector; Glycoprotein E; Varicella-zoster virus.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests.Sun Ok Jang, Jae Hyun Lee, Yong-Ju Chung, Hyun-Seok Oh, Myeongcheol Shin, Soo-Ok Kim, Sun Pyo Hong reports financial support was provided by Ministry of Food and Drug Safety. Kim, S. HS, Kim S, Jang S, Kim H, Lee S has patent licensed to GeneMatrix, Inc. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

Publication types

MeSH terms

Substances

LinkOut - more resources